Efficacy and Safety of SHR-1210 Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial

• The combination of SHR-1210 and apatinib yielded an objective response rate of 31.1% and a disease control rate of 75.6% in advanced hepatocellular carcinoma. • Median progression-free survival was 5.8 months and median overall survival was 12.3 months, suggesting durable clinical benefit. • The safety profile was manageable, with hypertension, proteinuria, and fatigue being the most common treatment-related adverse events. • This phase II trial provides a strong rationale for a phase III randomized study of this combination in advanced HCC.